Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation Positive booster data ...

Oct 28 (Reuters) - Britain's GSK (GSK.L), opens new tab cautioned full-year earnings would likely come in at the lower end of its forecast range after the COVID-19 pandemic took a toll on its vaccines ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. Pfizer and ...

GSK has successfully appealed a ruling by the U.K. marketing watchdog that determined a trio of its COVID-19 vaccine press releases had brought discredit on the pharma industry. The case is the latest ...

Add Yahoo as a preferred source to see more of our stories on Google. Donald Trump has repeatedly accused Pfizer of helping Joe Biden win the 2020 election - Francis Chung/Politico/Bloomberg Donald ...

Learn about the companies that are manufacturing vaccines and what you should know before investing in vaccine stocks.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain’s GSK and Germany’s CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

Moderna MRNA recently secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine. The decision is a significant milestone for the company, which gets an opportunity to establish a ...

CureVac (NASDAQ:CVAC) announced on Friday that the company and its partner, GSK (NYSE:GSK), are set to receive $740M and other payments, as Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have agreed to ...

Sanofi said May 17 it will soon launch a late-stage trial for the COVID-19 vaccine it is developing with GlaxoSmithKline after the vaccine produced a strong immune response in phase 2 trial ...